新型冠状病毒感染与银屑病之间关系的研究进展

doi:10.35541/cjd.20220869

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (1): 84-88.doi: 10.35541/cjd.20220869

新型冠状病毒感染与银屑病之间关系的研究进展

陈嘉琪¹ 张禁² 唐隽¹

¹中国科学技术大学附属第一医院安徽省立医院皮肤科，合肥 230001；²武警武汉特勤疗养中心，武汉 430000

收稿日期:2022-12-05 修回日期:2023-04-24 发布日期:2025-01-03
通讯作者: 唐隽 E-mail:tangjun0212@ustc.edu.cn
基金资助:
国家自然科学基金（82273516）；安徽省重点研究与开发计划项目（202004j07020002）

Relationships between coronavirus disease 2019 and psoriasis

Chen Jiaqi¹, Zhang Jin², Tang Jun¹

¹Department of Dermatology, the First Affiliated Hospital of University of Science and Technology of China（Anhui Provincial Hospital）, Hefei 230001, China; ²Wuhan Special Service Recuperation Center of Armed Policy, Wuhan 430000, China

Received:2022-12-05 Revised:2023-04-24 Published:2025-01-03
Contact: Tang Jun E-mail:tangjun0212@ustc.edu.cn
Supported by:
National Natural Science Foundation of China （82273516）; Anhui Provincial Key Research and Development Plan of China （202004j07020002）

摘要/Abstract

摘要： 【摘要】在新型冠状病毒（简称新冠病毒）感染大流行期间银屑病的管理引起了广泛关注，越来越多的研究者从不同角度探究银屑病与新冠病毒感染之间的关系。本文回顾银屑病患者使用生物制剂对新冠病毒感染的影响，以及银屑病与新冠病毒感染之间的相互作用，旨在为皮肤科医生和银屑病患者提供更为可靠的诊疗指导，为后续研究提供一定的参考依据。

关键词: 银屑病, 冠状病毒感染, 生物制剂, 羟氯喹, 新型冠状病毒感染

Abstract: 【Abstract】 During the coronavirus disease 2019 （COVID-19） pandemic, widespread attention has been paid to the management of psoriasis, and more and more researchers have explored the relationships between psoriasis and COVID-19 from different perspectives. This review summarizes the impact of the use of biological agents on COVID-19 in patients with psoriasis, and the interaction between psoriasis and COVID-19, aiming to provide more reliable guidance on diagnosis and treatment of psoriasis for dermatologists and patients, and to provide a reference for future research.

Key words: Psoriasis, Coronavirus infections, Biological agents, Hydroxychloroquine, COVID-19

陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025,58(1):84-88. doi:10.35541/cjd.20220869

Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis[J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88.doi:10.35541/cjd.20220869

参考文献 55

［1］	Lebwohl M, Rivera⁃Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID⁃19?［J］. J Am Acad Dermatol, 2020,82（5）:1217⁃1218. doi: 10.1016/j.jaad.2020.03. 031.
［2］	Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID⁃19 in patients with psoriasis receiving biological treatment: a Northern Italy experience［J］. J Allergy Clin Immunol, 2021,147（2）:558⁃560.e1. doi: 10.1016/j.jaci.2020.10.032.
［3］	Piaserico S, Gisondi P, Cazzaniga S, et al. Lack of evidence for an increased risk of severe COVID⁃19 in psoriasis patients on biologics: a cohort study from Northeast Italy［J］. Am J Clin Dermatol, 2020,21（5）:749⁃751. doi: 10.1007/s40257⁃020⁃00552⁃w.
［4］	Baniandrés⁃Rodríguez O, Vilar⁃Alejo J, Rivera R, et al. Incidence of severe COVID⁃19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis［J］. J Am Acad Dermatol, 2021,84（2）:513⁃517. doi: 10.1016/j.jaad.2020.10.046.
［5］	Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID⁃19 pandemic: risk analysis from the PSO⁃BIO⁃COVID observational study［J］. Expert Opin Biol Ther, 2021,21（2）:271⁃277. doi: 10.1080/14712598.2021.1853698.
［6］	Conti A, Lasagni C, Bigi L, et al. Evolution of COVID⁃19 infection in four psoriatic patients treated with biological drugs［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e360⁃e361. doi: 10.1111/jdv.16587.
［7］	Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS⁃CoV⁃2 infection and hospitalization, but not ICU admission and death: real⁃life data from a large cohort during red⁃zone declaration［J］. Dermatol Ther, 2020,33（5）:e13475. doi: 10.1111/dth.13475.
［8］	Valenti M, Facheris P, Pavia G, et al. Non⁃complicated evolution of COVID⁃19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab［J］. Dermatol Ther, 2020,33（4）:e13708. doi: 10.1111/dth.13708.
［9］	Ohmura SI, Homma Y, Hanai S, et al. Successful use of certolizumab pegol for refractory psoriatic arthritis triggered by COVID⁃19 infection［J］. Intern Med, 2022,61（3）:433⁃438. doi: 10.2169/internalmedicine.8643⁃21.
［10］	Carugno A, Gambini DM, Raponi F, et al. Coronavirus disease 2019 （COVID⁃19） rash in a psoriatic patient treated with secukinumab: is there a role for interleukin 17?［J］. Dermatol Ther, 2020,33（6）:e14011. doi: 10.1111/dth.14011.
［11］	Messina F, Piaserico S. SARS⁃CoV⁃2 infection in a psoriatic patient treated with IL⁃23 inhibitor［J］. J Eur Acad Dermatol Venereol, 2020,34（6）:e254⁃e255. doi: 10.1111/jdv.16468.
［12］	Kiss N, Lőrincz K, Medvecz M, et al. Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab［J］. Dermatol Ther, 2020,33（6）:e14186. doi: 10.1111/dth.14186.
［13］	Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019⁃nCoV: host⁃directed therapies should be an option［J］. Lancet, 2020,395（10224）:e35⁃e36. doi: 10.1016/S0140⁃6736（20）30305⁃ 6.
［14］	Mroz M, Mućka S, Miodońska M, et al. Influence of SARS⁃CoV⁃2 virus infection on the course of psoriasis during treatment with biological drugs［J］. Medicina （Kaunas）, 2021,57（9）:881. doi: 10.3390/medicina57090881.
［15］	Meng Y, Zeng F, Sun H, et al. Clinical characteristics and outcomes of patients with COVID⁃19 and psoriasis［J］. J Med Virol, 2022,94（12）:5850⁃5857. doi: 10.1002/jmv.28085.
［16］	Zhang M, Bai X, Cao W, et al. The influence of corticosteroids, immunosuppressants and biologics on patients with inflammatory bowel diseases, psoriasis and rheumatic diseases in the era of COVID⁃19: a review of current evidence［J］. Front Immunol, 2021,12:677957. doi: 10.3389/fimmu.2021.677957.
［17］	Penso L, Dray⁃Spira R, Weill A, et al. Psoriasis⁃related treatment exposure and hospitalization or in⁃hospital mortality due to COVID⁃19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France［J］. Br J Dermatol, 2022,186（1）:59⁃68. doi: 10.1111/bjd.20659.
［18］	Gisondi P, Zaza G, Del Giglio M, et al. Risk of hospitalization and death from COVID⁃19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment［J］. J Am Acad Dermatol, 2020,83（1）:285⁃287. doi: 10.1016/j.jaad.2020.04.085.
［19］	Kridin K, Schonmann Y, Tzur Bitan D, et al. Coronavirus disease 2019 （COVID⁃19）⁃associated hospitalization and mortality in patients with psoriasis: a population⁃based study［J］. Am J Clin Dermatol, 2021,22（5）:709⁃718. doi: 10.1007/s40257⁃021⁃00605⁃8.
［20］	Kara Polat A, Oguz Topal I, Karadag AS, et al. The impact of COVID⁃19 in patients with psoriasis: a multicenter study in Istanbul［J］. Dermatol Ther, 2021,34（1）:e14691. doi: 10.1111/dth.14691.
［21］	Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS⁃CoV⁃2 in Wuhan, China［J］. Allergy, 2020,75（7）:1730⁃1741. doi: 10.1111/all.14238.
［22］	Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID⁃19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study［J］. Ann Rheum Dis, 2020,79（12）:1544⁃1549. doi: 10.1136/annrheumdis⁃2020⁃218296.
［23］	Kutlu Ö, Metin A. Dermatological diseases presented before COVID⁃19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID⁃19?［J］. Dermatol Ther, 2020,33（4）:e13509. doi: 10.1111/dth.13509.
［24］	Yiu Z, Harding⁃Oredugba G, Griffiths C, et al. Risk of COVID⁃19 infection in adult patients with atopic eczema and psoriasis: a single⁃centre cross⁃sectional study［J］. Br J Dermatol, 2021,185（2）:441⁃443. doi: 10.1111/bjd.20062.
［25］	Haberman R, Axelrad J, Chen A, et al. Covid⁃19 in immune⁃mediated inflammatory diseases ⁃ case series from New York［J］. N Engl J Med, 2020,383（1）:85⁃88. doi: 10.1056/NEJMc 2009567.
［26］	Criado PR, Ianhez M, Silva de Castro CC, et al. COVID⁃19 and skin diseases: results from a survey of 843 patients with atopic dermatitis, psoriasis, vitiligo and chronic urticaria［J］. J Eur Acad Dermatol Venereol, 2022,36（1）:e1⁃e3. doi: 10.1111/jdv. 17635.
［27］	Eder L, Croxford R, Drucker AM, et al. COVID⁃19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune⁃mediated inflammatory diseases compared to controls［J］. J Rheumatol, 2022,49（5）:523⁃530. doi: 10.3899/jrheum.211012.
［28］	Gianfrancesco M, Hyrich KL, Al⁃Adely S, et al. Characteristics associated with hospitalisation for COVID⁃19 in people with rheumatic disease: data from the COVID⁃19 Global Rheumatology Alliance physician⁃reported registry［J］. Ann Rheum Dis, 2020,79（7）:859⁃866. doi: 10.1136/annrheumdis⁃2020⁃217871.
［29］	Carugno A, Gambini DM, Raponi F, et al. COVID⁃19 and biologics for psoriasis: a high⁃epidemic area experience⁃Bergamo, Lombardy, Italy［J］. J Am Acad Dermatol, 2020,83（1）:292⁃294. doi: 10.1016/j.jaad.2020.04.165.
［30］	Magnano M, Balestri R, Bardazzi F, et al. Psoriasis, COVID⁃19, and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment［J］. Dermatol Ther, 2020,33（4）:e13706. doi: 10.1111/dth.13706.
［31］	Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID⁃19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience［J］. Br J Dermatol, 2020,183（2）:373⁃374. doi: 10.1111/bjd.19158.
［32］	Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative［J］. Australas J Dermatol, 2019,60（2）:91⁃98. doi: 10.1111/ajd.12895.
［33］	Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry （PSOLAR）［J］. JAMA Dermatol, 2015,151（9）:961⁃969. doi: 10.1001/jamadermatol.2015.0718.
［34］	Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID⁃19 outcomes in patients with psoriasis⁃insights from a global registry⁃based study［J］. J Allergy Clin Immunol, 2021,147（1）:60⁃71. doi: 10.1016/j.jaci.2020.10.007.
［35］	Kampylafka E, Simon D, d′Oliveira I, et al. Disease interception with interleukin⁃17 inhibition in high⁃risk psoriasis patients with subclinical joint inflammation⁃data from the prospective IVEPSA study［J］. Arthritis Res Ther, 2019,21（1）:178. doi: 10.1186/s13075⁃019⁃1957⁃0.
［36］	Cronin JG, Mesher D, Purdie K, et al. Beta⁃papillomaviruses and psoriasis: an intra⁃patient comparison of human papillomavirus carriage in skin and hair［J］. Br J Dermatol, 2008,159（1）:113⁃119. doi: 10.1111/j.1365⁃2133.2008.08627.x.
［37］	Agarwal A, Tripathy T, Kar BR. Guttate flare in a patient with chronic plaque psoriasis following COVID⁃19 infection: a case report［J］. J Cosmet Dermatol, 2021,20（10）:3064⁃3065. doi: 10. 1111/jocd.14396.
［38］	Pala E, Melikoğlu M, Erkayman MH. Pediatric COVID⁃19 patient with exacerbated generalized pustular psoriasis［J］. Rev Soc Bras Med Trop, 2021,54:e0318. doi: 10.1590/0037⁃8682⁃0318⁃2021.
［39］	Bozonnat A, Assan F, LeGoff J, et al. SARS⁃CoV⁃2 infection inducing severe flare up of deficiency of interleukin thirty⁃six （IL⁃36） receptor antagonist （DITRA） resulting from a mutation invalidating the activating cleavage site of the IL⁃36 receptor antagonist［J］. J Clin Immunol, 2021,41（7）:1511⁃1514. doi: 10. 1007/s10875⁃021⁃01076⁃6.
［40］	Miladi R, Janbakhsh A, Babazadeh A, et al. Pustular psoriasis flare⁃up in a patient with COVID⁃19［J］. J Cosmet Dermatol, 2021,20（11）:3364⁃3368. doi: 10.1111/jocd.14508.
［41］	Shakoei S, Ghanadan A, Hamzelou S. Pustular psoriasis exacerbated by COVID⁃19 in a patient with the history of psoriasis［J］. Dermatol Ther, 2020,33（6）:e14462. doi: 10.1111/dth.14462.
［42］	Shahidi Dadras M, Diab R, Ahadi M, et al. Generalized pustular psoriasis following COVID⁃19［J］. Dermatol Ther, 2021,34（1）:e14595. doi: 10.1111/dth.14595.
［43］	Demiri J, Abdo M, Tsianakas A. Erythrodermic psoriasis after COVID⁃19［J］. Hautarzt, 2022,73（2）:156⁃159. doi: 10.1007/s00105⁃021⁃04931⁃0.
［44］	Nasiri S, Araghi F, Tabary M, et al. A challenging case of psoriasis flare⁃up after COVID⁃19 infection［J］. J Dermatolog Treat, 2020,31（5）:448⁃449. doi: 10.1080/09546634.2020.1764904.
［45］	Ozaras R, Berk A, Ucar DH, et al. Covid⁃19 and exacerbation of psoriasis［J］. Dermatol Ther, 2020,33（4）:e13632. doi: 10.1111/dth.13632.
［46］	Novelli L, Motta F, Ceribelli A, et al. A case of psoriatic arthritis triggered by SARS⁃CoV⁃2 infection［J］. Rheumatology （Oxford）, 2021,60（1）:e21⁃e23. doi: 10.1093/rheumatology/keaa691.
［47］	Zhou Q, Vadakekolathu J, Watad A, et al. SARS⁃CoV⁃2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type⁃1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights［J］. Front Immunol, 2021,12:635018. doi: 10.3389/fimmu.2021. 635018.
［48］	Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID⁃19⁃related death using OpenSAFELY［J］. Nature, 2020,584（7821）:430⁃436. doi: 10.1038/s41586⁃020⁃2521⁃4.
［49］	Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis［J］. Int J Mol Sci, 2019,20（18）:4347. doi: 10.3390/ijms20184347.
［50］	Shindo E, Shikano K, Kawazoe M, et al. A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus［J］. Lupus, 2019,28（8）:1017⁃1020. doi: 10.1177/0961203319854139.
［51］	Gravani A, Gaitanis G, Zioga A, et al. Synthetic antimalarial drugs and the triggering of psoriasis ⁃ do we need disease⁃specific guidelines for the management of patients with psoriasis at risk of malaria?［J］. Int J Dermatol, 2014,53（3）:327⁃330. doi: 10.1111/ijd.12231.
［52］	Ullah A, Zeb H, Khakwani Z, et al. Hydroxychloroquine⁃induced inverse psoriasis［J］. BMJ Case Rep, 2019,12（2）:e224619. doi: 10.1136/bcr⁃2018⁃224619.
［53］	Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID⁃19: will cases of psoriasis increase after COVID⁃19 pandemic?［J］. Dermatol Ther, 2020,33（4）:e13383. doi: 10.1111/dth.13383.
［54］	Wolf R, Schiavo AL, Lombardi ML, et al. The in vitro effect of hydroxychloroquine on skin morphology in psoriasis［J］. Int J Dermatol, 1999,38（2）:154⁃157. doi: 10.1046/j.1365⁃4362.1999. 00574.x.
［55］	Said A, Bock S, Lajqi T, et al. Chloroquine promotes IL⁃17 production by CD4+ T cells via p38⁃dependent IL⁃23 release by monocyte⁃derived Langerhans⁃like cells［J］. J Immunol, 2014,193（12）:6135⁃6143. doi: 10.4049/jimmunol.1303276.

[1]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 58(3): 20220881-e20220881.
[2]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[3]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.
[4]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[5]	窦进法王建波张帅李建国刘鸿伟张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 57(8): 739-742.
[6]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769.
[7]	隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574.
[8]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[9]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[10]	张元文孙从乾潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475.
[11]	郭澜晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478.
[12]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[13]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[14]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[15]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.

新型冠状病毒感染与银屑病之间关系的研究进展

Relationships between coronavirus disease 2019 and psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

Metrics

本文评价

推荐阅读 10